Krilogy Financial LLC Takes $1.25 Million Position in Amgen Inc. $AMGN

Krilogy Financial LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 4,416 shares of the medical research company’s stock, valued at approximately $1,246,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Laurel Wealth Advisors LLC raised its position in shares of Amgen by 27,765.8% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after acquiring an additional 6,676,575 shares in the last quarter. Norges Bank acquired a new stake in Amgen during the second quarter worth approximately $1,663,726,000. Vanguard Group Inc. increased its holdings in Amgen by 1.6% in the second quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock worth $14,996,807,000 after purchasing an additional 841,117 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Amgen by 5.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock valued at $3,600,043,000 after buying an additional 687,735 shares during the period. Finally, Mizuho Markets Cayman LP bought a new position in shares of Amgen during the 2nd quarter worth approximately $135,597,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

AMGN opened at $366.20 on Friday. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $385.12. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The company has a market capitalization of $197.19 billion, a price-to-earnings ratio of 25.73, a P/E/G ratio of 3.75 and a beta of 0.46. The firm’s fifty day moving average price is $336.68 and its two-hundred day moving average price is $313.14.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen’s revenue was up 8.6% on a year-over-year basis. During the same period last year, the business posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be paid a $2.52 dividend. The ex-dividend date is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a yield of 2.8%. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio (DPR) is presently 66.90%.

Analysts Set New Price Targets

AMGN has been the subject of a number of research reports. Wells Fargo & Company raised their price target on shares of Amgen from $300.00 to $325.00 and gave the stock an “equal weight” rating in a report on Wednesday, December 10th. Truist Financial increased their price objective on shares of Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research report on Thursday, January 8th. Guggenheim boosted their target price on Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. HSBC reiterated a “buy” rating and issued a $425.00 price target on shares of Amgen in a report on Wednesday, December 10th. Finally, Morgan Stanley boosted their price objective on Amgen from $304.00 to $309.00 and gave the company an “equal weight” rating in a report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Amgen presently has a consensus rating of “Moderate Buy” and an average target price of $354.04.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the sale, the senior vice president directly owned 7,225 shares in the company, valued at $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.76% of the stock is owned by insiders.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.